Protocol Ledger

NCT04851717 · Phase II/III · ACTIVE NOT RECRUITING

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

Interventional Phase II/III clinical trial protocol NCT04851717 sponsored by Acacia Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-15 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04851717
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04851717
Protocol FieldVerified Registry Value
NCT IdentifierNCT04851717
Consolidated Lead SponsorAcacia Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2021-11-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI